<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641537</url>
  </required_header>
  <id_info>
    <org_study_id>27820</org_study_id>
    <nct_id>NCT00641537</nct_id>
  </id_info>
  <brief_title>CLARITY Extension Study</brief_title>
  <official_title>A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects With Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <brief_summary>
    <textblock>
      The purpose of this extension trial is to further evaluate the safety and tolerability of
      oral cladribine in subjects who have previously completed treatment within Trial 25643
      (CLARITY). This trial also explored clinical benefit of prolonged 192-week versus 96-week
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 Lymphocyte Toxicity</measure>
    <time_frame>Baseline up to Week 120</time_frame>
    <description>Lymphocyte toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE). CTCAE grade for absolute lymphocyte counts included: Grade 1 = less than lower limit of normal; Grade 2 = less than 800 per cubic millimeter (/mm^3); Grade 3 = less than 500/mm^3; Grade 4 = less than 200/mm^3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to week 120</time_frame>
    <description>An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Time to Recovery From Grade 3 or 4 Lymphocyte Toxicity</measure>
    <time_frame>Baseline up to Week 120</time_frame>
    <description>Lymphocyte toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE). CTCAE grade for absolute lymphocyte counts included: Grade 1 = less than lower limit of normal; Grade 2 = less than 800 per cubic millimeter (/mm^3); Grade 3 = less than 500/mm^3; Grade 4 = less than 200/mm^3. Recovery from a Grade 3 or 4 toxicity is defined as a return to a Grade 0 or 1 during the CLARITY Extension Study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Developed Herpes Zoster Infections and Malignancies</measure>
    <time_frame>Baseline up to Week 120</time_frame>
    <description>Herpes zoster infection is defined as having at least one adverse event coded to medical dictionary for regulatory activities (MedDRA) preferred terms herpes zoster, herpes zoster iridocyclitis, herpes zoster ophthalmic, herpes zoster multi-dermatomal, herpes zoster infection neurological, herpes zoster oticus. Malignancy is defined as having at least one adverse event coded to MedDRA preferred terms under the pre_specified grouping Malignant and unspecified tumors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized Qualifying Relapse Rate</measure>
    <time_frame>Week 96</time_frame>
    <description>A qualifying relapse was defined as an increase of 2 points in at least one functional system of the expanded disability status scale (EDSS) or an increase of 1 point in at least two functional systems (excluding changes in bowel or bladder function or cognition) in the absence of fever, lasting for at least 24 hours and to have been preceded by at least 30 days of clinical stability or improvement. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis [MS]) was calculated. The annualized relapse rate for each treatment group was calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Combined Unique (CU) Lesions</measure>
    <time_frame>Week 96</time_frame>
    <description>Mean Number of CU lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disability Progression (Confirmed After 3 Months)</measure>
    <time_frame>Baseline up to Week 96</time_frame>
    <description>Time to disability progression was defined as the time to a sustained increase in EDSS score of at least 1 point if baseline EDSS score between 0.5 and 4.5 inclusively, or at least 1.5 points if the baseline EDSS score was 0, or at least 0.5 point if the baseline EDSS score was at least 5, over a period of at least three months. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. As few participants have reached EDSS progression, fourth Percentile of time to sustained increase in EDSS score was reported using Kaplan-Meier survival curve.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">867</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cladribine Low/Placebo (LLPP)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine High Dose/Placebo (HLPP)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine Low/Low Dose (LLLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine High/Low Dose (HLLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Cladribine Low Dose (PPLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.</description>
    <arm_group_label>Cladribine Low/Low Dose (LLLL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.</description>
    <arm_group_label>Cladribine Low/Placebo (LLPP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.</description>
    <arm_group_label>Cladribine High/Low Dose (HLLL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.</description>
    <arm_group_label>Placebo/Cladribine Low Dose (PPLL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.</description>
    <arm_group_label>Cladribine High Dose/Placebo (HLPP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Randomized in Trial 25643 and satisfied one of the following:

               -  Completed randomized treatment course and scheduled visits for the full 96 weeks;
                  or

               -  Did not complete the randomized treatment course in Trial 25643 but elected to
                  receive rescue treatment with Rebif®, another beta-interferon, or glatiramer
                  acetate and completed scheduled clinic visits for the full 96 weeks; or

               -  Did not complete the randomized treatment course in Trial 25643, declined rescue
                  with Rebif®, another beta-interferon, or glatiramer acetate and still completed
                  scheduled clinic visits for the full 96 weeks; or

               -  Did not complete the randomized treatment course in Trial 25643, were not
                  eligible for rescue option with Rebif®, and still completed scheduled clinic
                  visits for the full 96 weeks

          -  Male or female, between 18 and 65 years of age (inclusive, at time of informed consent
             for Trial 25643)

          -  No medical history or evidence of latent tuberculosis infection (LTBI) or tuberculosis
             (TB), as evidenced by TB skin test or chest X-ray

          -  All of the following laboratory hematologic parameters evaluated as normal (as define
             below, inclusively) within 28 days of first dosing of blinded study medication at
             study Day 1:

               -  Hemoglobin = 11.6 to 16.2 gram per deciliter (g/dL)

               -  Leukocytes (total white blood cell) = 4.1 to 12.3*10^3 per microliter

               -  Absolute lymphocyte count (ALC) = 1.02 to 3.36*10^3 per microliter

               -  Absolute neutrophil count (ANC) = 2.03 to 8.36*10^3 per microliter

               -  Platelet count = 140 to 450*10^3 per microliter

          -  Other protocol-defined inclusion/exclusion criteria may apply

        Exclusion Criteria:

          -  Subjects who were not enrolled in Trial 25643

          -  Subject has moderate to severe renal impairment

          -  Use of mitoxantrone, total lymphoid irradiation, myelosuppressive therapy, campath-1h,
             cyclophosphamide, azathioprine, methotrexate or natalizumab at any time during and
             since Trial 25643

          -  Use of cytokine or anti-cytokine therapy, intravenous immunoglobulin (IVIG) or
             plasmapheresis at any time during and since Trial 25643

          -  Treatment with oral or systemic corticosteroids or adrenocorticotropic hormone within
             28 days before Study Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Victoria</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Diepenbeek</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Esneux</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shuman</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burnaby</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenfield Park</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karlovac</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sisak</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Split</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beyrouth</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Casablanca</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fes</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rabat</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sittard- Geleen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawy</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaluga</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reseach Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladimir</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monastir</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sfax</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stoke-on-Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lebanon</country>
    <country>Lithuania</country>
    <country>Morocco</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Serbia</country>
    <country>Switzerland</country>
    <country>Tunisia</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <results_first_submitted>September 30, 2013</results_first_submitted>
  <results_first_submitted_qc>September 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2013</results_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cladribine Low/Placebo (LLPP)</title>
          <description>Participants who received cladribine 3.5 milligram/kilogram (mg/kg) in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="P2">
          <title>Cladribine High Dose/Placebo (HLPP)</title>
          <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="P3">
          <title>Cladribine Low/Low Dose (LLLL)</title>
          <description>Participants who received Cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="P4">
          <title>Cladribine High/Low Dose (HLLL)</title>
          <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="P5">
          <title>Placebo/Cladribine Low Dose (PPLL)</title>
          <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received Cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="P6">
          <title>Placebo/No Treatment</title>
          <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
        </group>
        <group group_id="P7">
          <title>Cladribine 3.5 mg/kg/No Treatment</title>
          <description>Participants who received Cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
        </group>
        <group group_id="P8">
          <title>Cladribine 5.25 mg/kg/No Treatment</title>
          <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>96-week Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="186"/>
                <participants group_id="P4" count="186"/>
                <participants group_id="P5" count="244"/>
                <participants group_id="P6" count="22"/>
                <participants group_id="P7" count="17"/>
                <participants group_id="P8" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="166"/>
                <participants group_id="P4" count="174"/>
                <participants group_id="P5" count="226"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>24-Week Supplemental Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="143"/>
                <participants group_id="P4" count="151"/>
                <participants group_id="P5" count="198"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="140"/>
                <participants group_id="P4" count="147"/>
                <participants group_id="P5" count="193"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat (ITT) population included all participants who were randomized in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Cladribine Low/Placebo (LLPP)</title>
          <description>Participants who received cladribine 3.5 milligram/kilogram (mg/kg) in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="B2">
          <title>Cladribine High Dose/Placebo (HLPP)</title>
          <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="B3">
          <title>Cladribine Low/Low Dose (LLLL)</title>
          <description>Participants who received Cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="B4">
          <title>Cladribine High/Low Dose (HLLL)</title>
          <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="B5">
          <title>Placebo/Cladribine Low Dose (PPLL)</title>
          <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received Cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="92"/>
            <count group_id="B3" value="186"/>
            <count group_id="B4" value="186"/>
            <count group_id="B5" value="244"/>
            <count group_id="B6" value="806"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.7" spread="10.7"/>
                    <measurement group_id="B2" value="40.8" spread="9.6"/>
                    <measurement group_id="B3" value="40.6" spread="10.5"/>
                    <measurement group_id="B4" value="41.4" spread="10.1"/>
                    <measurement group_id="B5" value="41.6" spread="9.6"/>
                    <measurement group_id="B6" value="41.1" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="156"/>
                    <measurement group_id="B6" value="531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="88"/>
                    <measurement group_id="B6" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 Lymphocyte Toxicity</title>
        <description>Lymphocyte toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE). CTCAE grade for absolute lymphocyte counts included: Grade 1 = less than lower limit of normal; Grade 2 = less than 800 per cubic millimeter (/mm^3); Grade 3 = less than 500/mm^3; Grade 4 = less than 200/mm^3.</description>
        <time_frame>Baseline up to Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 milligram/kilogram (mg/kg) in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received Cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received Cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 Lymphocyte Toxicity</title>
          <description>Lymphocyte toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE). CTCAE grade for absolute lymphocyte counts included: Grade 1 = less than lower limit of normal; Grade 2 = less than 800 per cubic millimeter (/mm^3); Grade 3 = less than 500/mm^3; Grade 4 = less than 200/mm^3.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="186"/>
                <count group_id="O4" value="186"/>
                <count group_id="O5" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 Lymphocyte toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="6.5"/>
                    <measurement group_id="O3" value="38.1"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 Lymphocyte toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="3.2"/>
                    <measurement group_id="O5" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Qualifying Relapse Rate</title>
        <description>A qualifying relapse was defined as an increase of 2 points in at least one functional system of the expanded disability status scale (EDSS) or an increase of 1 point in at least two functional systems (excluding changes in bowel or bladder function or cognition) in the absence of fever, lasting for at least 24 hours and to have been preceded by at least 30 days of clinical stability or improvement. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis [MS]) was calculated. The annualized relapse rate for each treatment group was calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.</description>
        <time_frame>Week 96</time_frame>
        <population>Intention-to-treat (ITT) population included all participants who were randomized in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 milligram/kilogram (mg/kg) in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received Cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received Cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Qualifying Relapse Rate</title>
          <description>A qualifying relapse was defined as an increase of 2 points in at least one functional system of the expanded disability status scale (EDSS) or an increase of 1 point in at least two functional systems (excluding changes in bowel or bladder function or cognition) in the absence of fever, lasting for at least 24 hours and to have been preceded by at least 30 days of clinical stability or improvement. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis [MS]) was calculated. The annualized relapse rate for each treatment group was calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.</description>
          <population>Intention-to-treat (ITT) population included all participants who were randomized in the study.</population>
          <units>relapses per year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="186"/>
                <count group_id="O4" value="186"/>
                <count group_id="O5" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.08" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.09" upper_limit="0.23"/>
                    <measurement group_id="O3" value="0.10" lower_limit="0.06" upper_limit="0.14"/>
                    <measurement group_id="O4" value="0.11" lower_limit="0.07" upper_limit="0.15"/>
                    <measurement group_id="O5" value="0.10" lower_limit="0.07" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Combined Unique (CU) Lesions</title>
        <description>Mean Number of CU lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
        <time_frame>Week 96</time_frame>
        <population>ITT population included all participants who were randomized in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 milligram/kilogram (mg/kg) in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received Cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received Cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Combined Unique (CU) Lesions</title>
          <description>Mean Number of CU lesions were measured by using magnetic resonance imaging (MRI) scans.</description>
          <population>ITT population included all participants who were randomized in the study.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="186"/>
                <count group_id="O4" value="186"/>
                <count group_id="O5" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88" spread="15.31"/>
                    <measurement group_id="O2" value="6.02" spread="9.22"/>
                    <measurement group_id="O3" value="3.97" spread="7.18"/>
                    <measurement group_id="O4" value="5.53" spread="14.79"/>
                    <measurement group_id="O5" value="5.10" spread="9.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disability Progression (Confirmed After 3 Months)</title>
        <description>Time to disability progression was defined as the time to a sustained increase in EDSS score of at least 1 point if baseline EDSS score between 0.5 and 4.5 inclusively, or at least 1.5 points if the baseline EDSS score was 0, or at least 0.5 point if the baseline EDSS score was at least 5, over a period of at least three months. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. As few participants have reached EDSS progression, fourth Percentile of time to sustained increase in EDSS score was reported using Kaplan-Meier survival curve.</description>
        <time_frame>Baseline up to Week 96</time_frame>
        <population>ITT population included all participants who were randomized in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 milligram/kilogram (mg/kg) in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received Cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received Cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disability Progression (Confirmed After 3 Months)</title>
          <description>Time to disability progression was defined as the time to a sustained increase in EDSS score of at least 1 point if baseline EDSS score between 0.5 and 4.5 inclusively, or at least 1.5 points if the baseline EDSS score was 0, or at least 0.5 point if the baseline EDSS score was at least 5, over a period of at least three months. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. As few participants have reached EDSS progression, fourth Percentile of time to sustained increase in EDSS score was reported using Kaplan-Meier survival curve.</description>
          <population>ITT population included all participants who were randomized in the study.</population>
          <units>months</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="186"/>
                <count group_id="O4" value="186"/>
                <count group_id="O5" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="5.5"/>
                    <measurement group_id="O3" value="8.2"/>
                    <measurement group_id="O4" value="5.5"/>
                    <measurement group_id="O5" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.</description>
        <time_frame>Baseline up to week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 milligram/kilogram (mg/kg) in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received Cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received Cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="186"/>
                <count group_id="O4" value="186"/>
                <count group_id="O5" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="149"/>
                    <measurement group_id="O4" value="149"/>
                    <measurement group_id="O5" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Time to Recovery From Grade 3 or 4 Lymphocyte Toxicity</title>
        <description>Lymphocyte toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE). CTCAE grade for absolute lymphocyte counts included: Grade 1 = less than lower limit of normal; Grade 2 = less than 800 per cubic millimeter (/mm^3); Grade 3 = less than 500/mm^3; Grade 4 = less than 200/mm^3. Recovery from a Grade 3 or 4 toxicity is defined as a return to a Grade 0 or 1 during the CLARITY Extension Study.</description>
        <time_frame>Baseline up to Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. 'N' signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 milligram/kilogram (mg/kg) in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received Cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received Cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Recovery From Grade 3 or 4 Lymphocyte Toxicity</title>
          <description>Lymphocyte toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE). CTCAE grade for absolute lymphocyte counts included: Grade 1 = less than lower limit of normal; Grade 2 = less than 800 per cubic millimeter (/mm^3); Grade 3 = less than 500/mm^3; Grade 4 = less than 200/mm^3. Recovery from a Grade 3 or 4 toxicity is defined as a return to a Grade 0 or 1 during the CLARITY Extension Study.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. 'N' signifies number of participants who were evaluable for this outcome measure.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="13" upper_limit="84"/>
                    <measurement group_id="O2" value="30.5" lower_limit="24.5" upper_limit="50"/>
                    <measurement group_id="O3" value="211" lower_limit="7" upper_limit="1183"/>
                    <measurement group_id="O4" value="167" lower_limit="6" upper_limit="798"/>
                    <measurement group_id="O5" value="110.3" lower_limit="4" upper_limit="700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Developed Herpes Zoster Infections and Malignancies</title>
        <description>Herpes zoster infection is defined as having at least one adverse event coded to medical dictionary for regulatory activities (MedDRA) preferred terms herpes zoster, herpes zoster iridocyclitis, herpes zoster ophthalmic, herpes zoster multi-dermatomal, herpes zoster infection neurological, herpes zoster oticus. Malignancy is defined as having at least one adverse event coded to MedDRA preferred terms under the pre_specified grouping Malignant and unspecified tumors.</description>
        <time_frame>Baseline up to Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 milligram/kilogram (mg/kg) in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received Cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received Cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Herpes Zoster Infections and Malignancies</title>
          <description>Herpes zoster infection is defined as having at least one adverse event coded to medical dictionary for regulatory activities (MedDRA) preferred terms herpes zoster, herpes zoster iridocyclitis, herpes zoster ophthalmic, herpes zoster multi-dermatomal, herpes zoster infection neurological, herpes zoster oticus. Malignancy is defined as having at least one adverse event coded to MedDRA preferred terms under the pre_specified grouping Malignant and unspecified tumors.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="186"/>
                <count group_id="O4" value="186"/>
                <count group_id="O5" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Herpes Zoster Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected from baseline up to Week 96 and 24-Week supplemental follow-up period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cladribine Low/Placebo (LLPP)</title>
          <description>Participants who received cladribine 3.5 milligram/kilogram (mg/kg) in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="E2">
          <title>Cladribine High Dose/Placebo (HLPP)</title>
          <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received placebo matched to cladribine tablet 0.875 mg/kg orally over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="E3">
          <title>Cladribine Low/Low Dose (LLLL)</title>
          <description>Participants who received Cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="E4">
          <title>Cladribine High/Low Dose (HLLL)</title>
          <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="E5">
          <title>Placebo/Cladribine Low Dose (PPLL)</title>
          <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and completed were re-randomized in this extension study and received Cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="E6">
          <title>Placebo/No Treatment</title>
          <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
        </group>
        <group group_id="E7">
          <title>Cladribine 3.5 mg/kg/No Treatment</title>
          <description>Participants who received Cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
        </group>
        <group group_id="E8">
          <title>Cladribine 5.25 mg/kg/No Treatment</title>
          <description>Participants who received Cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
        </group>
        <group group_id="E9">
          <title>Cladribine Low/Placebo (LLPP) (24-week Follow-up Period)</title>
          <description>Participants who received placebo matched to cladribine tablet during the treatment period of 96 weeks were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="E10">
          <title>Cladribine High Dose/Placebo (HLPP) (24-week Follow-up Period</title>
          <description>Participants who received placebo matched to cladribine tablet during the treatment period of 96 weeks were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="E11">
          <title>Cladribine Low/Low Dose (LLLL) (24-week Follow-up Period)</title>
          <description>Participants who received cladribine 3.5 mg/kg during the treatment period of 96 weeks were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="E12">
          <title>Cladribine High/Low Dose (HLLL) (24-week Follow-up Period)</title>
          <description>Participants who received cladribine 3.5 mg/kg during the treatment period of 96 weeks were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="E13">
          <title>Placebo/Cladribine Low Dose (PPLL) (24-week Follow-up Period)</title>
          <description>Participants who received cladribine 3.5 mg/kg during the treatment period of 96 weeks were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="E14">
          <title>Placebo/No Treatment (24-week Follow-up Period)</title>
          <description>Participants who received no cladribine treatment during 96 weeks were followed up for 24-Week supplemental follow-up period.</description>
        </group>
        <group group_id="E15">
          <title>Cladribine 3.5 mg/kg/No Treatment (24-week Follow-up Period)</title>
          <description>Participants who received no cladribine treatment during 96 weeks were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
        <group group_id="E16">
          <title>Cladribine 5.25 mg/kg/No Treatment (24-week Follow-up Period)</title>
          <description>Participants who received no cladribine treatment during 96 weeks were followed up for 24 weeks in supplemental follow-up period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Adams-Stokes syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Secondary immunodeficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urethral abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood culture positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pregnancy test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tuberculin test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Breast fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fibrous histiocytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Juvenile melanoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neurilemmoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="124" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="123" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="163" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="75" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="69" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Anaemia of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Erythema infectiosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Infected insect bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Red blood cell burr cells present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thyroid function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Serono, a division of Merck KGaA</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

